July 3, 2020
AbbVie Japan President James Feliciano AbbVie saw a dip in its Japan revenue in 2019 in a pullback from the previous year’s spike on the hepatitis C drug Maviret (glecaprevir + pibrentasvir), but its topline still crossed the 100 billion...read more